A Review of Nanoparticles in Treatment of Myocardiac Ischemic-Reperfusion Injury

  • Tszching Sung College of Pharmacy, Jinan University
  • Peiyang Qin College of Pharmacy, Jinan University
DOI: https://doi.org/10.18686/aem.v11i4.261
Keywords: Ischemia-Reperfusion Injury(Iri), Treatment, Myocardial Infarction(Mi), Nanoparticle(Nps), Pharmacodynamics, Targeting, Drug Delivery, Atherosclerosis, Reactive Oxygen Species (Ros), Drug

Abstract

Myocardial ischemia-reperfusion injury is a kind of pathologic physiology, clinical refers to, when myocardial or coronary artery in patients with partial completeness of acute obstruction, and leads to ischemia after a period of time, restore blood supply, at this time although the myocardium and coronary ischemia returned to normal perfusion, but they are so tissue level by damage, seriously affecting the prognosis of patients with myocardial infarction. Studies have proved that the injury caused by reperfusion is even more serious than that caused by ischemia itself. The mechanisms leading to myocardial ischemia-reperfusion injury mainly include :(1) calcium overload due to recovery of oxygen supply; (2) cardiac ultrastructural changes; (3) lipid peroxidation; (4) leukocyte infiltration; (5) Increase of free radical reactive oxygen species. Different approaches have been used clinically to reduce ischemia-reperfusion injury, including medication, pretreatment and post-treatment. In recent years, the targeting ability of nano-agents has been used to make drugs highly concentrated at the injury site, thus improving the therapeutic effect of drugs for ischemic-reperfusion injury. This emerging medication method has gradually entered the field of vision of experimental researchers and doctors. This review summarizes the successful development of nanoparticles for the treatment of myocardial ischemia-reperfusion injury.

References

[1] Li R, Rhee SJ, Bae S, et al. H2O2-Responsive Antioxidant Nanoparticle Attenuates Whole Body Ischemia/Reperfusion-Induced Multi-Organ Damages. J Cardiovasc Pharmacol Ther. 2021;26(3):279-288.

[2] Evers MJW, Du W, Yang Q, et al. Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles. J Control Release. 2022;343:207-216.

[3] Zhang Y, Ren X, Wang Y, et al. Targeting Ferroptosis by Polydopamine Nanoparticles Protects Heart against Ischemia/Reperfusion Injury. ACS Appl Mater Interfaces. 2021;13(45):53671-53682.

[4] Liu CJ, Yao L, Hu YM, Zhao BT. Effect of Quercetin-Loaded Mesoporous Silica Nanoparticles on Myocardial Ischemia-Reperfusion Injury in Rats and Its Mechanism. Int J Nanomedicine. 2021;16:741-752. Published 2021 Feb 2.

[5] Ikeda G, Matoba T, Ishikita A, et al. Nanoparticle-Mediated Simultaneous Targeting of Mitochondrial Injury and Inflammation Attenuates Myocardial Ischemia-Reperfusion Injury. J Am Heart Assoc. 2021;10(12):e019521.

[6] Ikeda G, Matoba T, Nakano Y, Nagaoka K, Ishikita A, Nakano K, Funamoto D, Sunagawa K, Egashira K. Nanoparticle‐mediated targeting of cyclosporine a enhances cardioprotection against ischemia‐reperfusion injury through inhibition of mitochondrial permeability transition pore opening. Sci Rep. 2016;6:20467.  

[7] Ichimura K, Matoba T, Nakano K, Tokutome M, Honda K, Koga J, Egashira K. A translational study of a new therapeutic approach for acute myocardial infarction: nanoparticle‐mediated delivery of pitavastatin into reperfused myocardium reduces ischemia‐reperfusion injury in a preclinical porcine model. PLoS One. 2016;11:e0162425.

[8] Lee JR, Park BW, Park JH, et al. Local delivery of a senolytic drug in ischemia and reperfusion-injured heart attenuates cardiac remodeling and restores impaired cardiac function. Acta Biomater. 2021;135:520-533.

[9] Sun X, Wang Y, Wen S, et al. Novel controlled and targeted releasing hydrogen sulfide system exerts combinational cerebral and myocardial protection after cardiac arrest. J Nanobiotechnology. 2021;19(1):40. Published 2021 Feb 6.

[10] Hou M, Wu X, Zhao Z, Deng Q, Chen Y, Yin L. Endothelial cell-targeting, ROS-ultrasensitive drug/siRNA co-delivery nanocomplexes mitigate early-stage neutrophil recruitment for the anti-inflammatory treatment of myocardial ischemia reperfusion injury. Acta Biomater. 2022;143:344-355.
Published
2023-03-02
Issue
Vol 11, No 4 (2022)
Section
Original Research Article

Copyright (c) 2023 Tszching Sung

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.